NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (enExample) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (enExample)
EP (6) EP1162998B1 (enExample)
JP (4) JP4846906B2 (enExample)
KR (3) KR20020000785A (enExample)
CN (3) CN100339130C (enExample)
AR (3) AR022965A1 (enExample)
AT (3) ATE346608T1 (enExample)
AU (3) AU750762B2 (enExample)
BE (1) BE1025464I2 (enExample)
BR (4) BR0009166A (enExample)
CA (3) CA2366152A1 (enExample)
CY (3) CY1107561T1 (enExample)
CZ (3) CZ20013378A3 (enExample)
DE (4) DE60038166T2 (enExample)
DK (2) DK1162999T3 (enExample)
ES (3) ES2339737T3 (enExample)
FR (1) FR10C0008I2 (enExample)
HK (3) HK1043730A1 (enExample)
HU (4) HU228499B1 (enExample)
IL (5) IL145044A0 (enExample)
LU (1) LU91652I2 (enExample)
MX (1) MXPA01009452A (enExample)
MY (2) MY125202A (enExample)
NL (1) NL300415I1 (enExample)
NO (4) NO330532B1 (enExample)
NZ (3) NZ513840A (enExample)
PL (3) PL204890B1 (enExample)
PT (2) PT1162999E (enExample)
SI (2) SI1163000T1 (enExample)
TR (3) TR200102739T2 (enExample)
TW (3) TWI235064B (enExample)
WO (3) WO2000056360A2 (enExample)

Families Citing this family (289)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ATE355375T1 (de) 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic Bakterioferritin aus helicobacter pylori
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
ES2339737T3 (es) 1999-03-19 2010-05-25 Glaxosmithkline Biologicals Sa Vacuna contra polisacaridos capsulares de streptococcus pneumoniae.
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1671981A3 (en) 2000-10-27 2006-07-05 Chiron SRL. Nucleic acids and proteins from streptococcus group A
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
HU230490B1 (hu) 2001-01-23 2016-08-29 Sanofi Pasteur Inc. Multivalens, meningokokkusz-eredetű poliszaccharid Ć©s fehĆ©rje konjugĆ”tumĆ”t tartalmazĆ³ vakcina
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
NZ562929A (en) 2001-12-12 2009-07-31 Novartis Vaccines & Diagnostic Immunisation against chlamydia trachomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
ES2607431T3 (es) 2002-02-20 2017-03-31 Glaxosmithkline Biologicals Sa Micropartƭculas con molƩculas que contienen polipƩptidos adsorbidos
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
US20060147466A1 (en) * 2002-05-14 2006-07-06 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
AU2003274011B2 (en) * 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
DE60311526T2 (de) 2002-11-01 2007-10-31 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzung
NZ539153A (en) 2002-11-12 2006-11-30 Brigham & Womens Hospital Polysaccharide vaccine for staphylococcal infections
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
AU2004220590B2 (en) 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
CN101818185B (zh) * 2003-03-13 2016-05-25 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ēŗÆ化ē»†čŒęŗ¶ē»†čƒžē“ ēš„ę–¹ę³•
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgĆ”nicos para la inmunopotenciaciĆ³n
EP2179729B1 (en) 2003-06-02 2016-07-20 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN103405761A (zh) * 2003-10-02 2013-11-27 čÆŗ华ē–«č‹—å’ŒčÆŠę–­ęœ‰é™å…¬åø 多ē§č„‘č†œē‚ŽēƒčŒč”€ęø…ē¾¤ēš„ę¶²ä½“ē–«č‹—
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
DK1740217T3 (da) 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
CA2598488A1 (en) 2005-02-18 2006-08-31 Novartis Vaccines And Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
JP2008529558A (ja) 2005-02-18 2008-08-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ é«„č†œē‚Žļ¼ę•—蔀ē—‡ć«é–¢é€£ć™ć‚‹å¤§č…ø菌ē”±ę„恮ć‚æćƒ³ćƒ‘ć‚Æč³ŖćŠć‚ˆć³ę øé…ø
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102220506B1 (ko) * 2005-04-08 2021-03-02 ģ™€ģ“ģ–“ģ“° ģ—˜ģ—˜ģ”Ø ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
EP2329843A3 (en) 2005-04-18 2011-09-14 Novartis Vaccines and Diagnostics, Inc. Expressing Hepatitis B Virus surface antigen for vaccine preparation
UA95238C2 (uk) 2005-06-27 2011-07-25 ŅŠ»Š°ŠŗсŠ¾ŃŠ¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Š· Š”.Š. Š†Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Š° ŠŗŠ¾Š¼ŠæŠ¾Š·Šøція
JP5135220B2 (ja) 2005-09-01 2013-02-06 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ćƒ“ć‚”ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚²ćƒ¼ć‚Øćƒ ćƒ™ćƒ¼ćƒćƒ¼ ć‚¢ćƒ³ćƒ‰ ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ć‚«ćƒ¼ć‚²ćƒ¼ 蔀ęø…ē¾¤ļ½ƒé«„č†œē‚ŽčŒć‚’å«ć‚€č¤‡ę•°ćƒÆć‚Æćƒćƒ³ęŽ„ēØ®
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101367237B1 (ko) 2005-12-22 2014-03-14 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ģŠ¤ķŠøė ™ķ† ģ½”ģæ ģŠ¤ ė‰“ėŖØė‹ˆģ•  ģŗ”ģŠ ė‹¤ė‹¹ė„˜ ģ»Øģ„¬ź²Œģ“ķŠøė„¼ ķ¬ķ•Øķ•˜ėŠ” ė°±ģ‹ 
JP5275814B2 (ja) * 2006-01-17 2013-08-28 惕ć‚Ŗćƒ«ć‚¹ćƒ¬ćƒ³ļ¼Œć‚¢ćƒ«ćƒ ę–°č¦č”Ø面露å‡ŗćƒ˜ćƒ¢ćƒ•ć‚£ćƒ«ć‚¹ćƒ»ć‚¤ćƒ³ćƒ•ćƒ«ć‚Øćƒ³ć‚¶ļ¼ˆļ¼Øļ¼”ļ¼„ļ¼­ļ¼Æļ¼°ļ¼Øļ¼©ļ¼¬ļ¼µļ¼³ļ¼©ļ¼®ļ¼¦ļ¼¬ļ¼µļ¼„ļ¼®ļ¼ŗļ¼”ļ¼„ļ¼‰ć‚æćƒ³ćƒ‘ć‚Æč³Ŗļ¼ˆć‚æćƒ³ćƒ‘ć‚Æč³Ŗļ¼„ļ¼›ļ½ļ¼„ļ¼‰
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
AU2007227504B2 (en) * 2006-03-17 2013-10-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. RegĆ­menes para inmunizaciĆ³n con conjugados meningocĆ³cicos
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
CL2007000839A1 (es) * 2006-03-30 2008-01-25 Glaxosmithline Biolog S A Procedimiento para producir un conjugado que comprende un polisacĆ”rido u oligosacĆ”rido de tipo 5 u 8 de s. aureus y una proteĆ­na portadora; conjugado inmunogĆ©nico que lo comprende; vacuna que comprende al conjugado; procedimiento de obtenciĆ³n de dicha vacuna; y uso del conjugado para tratar o prevenir la infecciĆ³n por estafilococos
BRPI0710210A2 (pt) * 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composiĆ§Ć£o imunogĆŖnica, vacina, mĆ©todos para preparar a vacina, e para prevenir ou tratar infecĆ§Ć£o estafilocĆ³cica, uso da composiĆ§Ć£o imunogĆŖnica, e, processo para conjugar oligassacarƬdeo ou polissacarƬdeo capsular
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2054431B1 (en) * 2006-06-09 2011-08-31 Novartis AG Conformers of bacterial adhesins
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
ES2346929T3 (es) * 2006-10-10 2010-10-21 Wyeth Llc Procedimientos mejorados para la separacion de polisacaridos de streptococcus pneumoniae de tipo 3.
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EA201391788A1 (ru) * 2007-06-26 2014-08-29 Š“Š»Š°ŠŗсŠ¾ŃŠ¼ŠøтŠŗŠ»Š°Š¹Š½ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶ŠøŠŗŠ°Š»Ń Š”.Š. Š’Š°ŠŗцŠøŠ½Š°, сŠ¾Š“ŠµŃ€Š¶Š°Ń‰Š°Ń ŠŗŠ¾Š½ŃŠŃŽŠ³Š°Ń‚Ń‹ ŠŗŠ°ŠæсуŠ»ŃŒŠ½Ń‹Ń… ŠæŠ¾Š»ŠøсŠ°Ń…Š°Ń€ŠøŠ“Š¾Š² streptococcus pneumoniae
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BRPI0816689B1 (pt) 2007-09-12 2021-08-24 Novartis Ag ComposiĆ§Ć£o de vacina, kit e mĆ©todo para a confecĆ§Ć£o de uma composiĆ§Ć£o de vacina para a prevenĆ§Ć£o ou tratamento de infecĆ§Ć£o por streptococcus pyogenes
MX2010004271A (es) 2007-10-19 2010-05-03 Novartis Ag Formulaciones de vacuna meningococica.
JP2011503104A (ja) 2007-11-09 2011-01-27 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 免ē–«čŖæēƀ化合ē‰©ćŖć‚‰ć³ć«é–¢é€£ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101977926B (zh) 2007-12-21 2014-10-08 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 链ēƒčŒęŗ¶č”€ē“ oēš„ēŖå˜å½¢å¼
AU2009208403A1 (en) * 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland ProteĆ­nas quimĆ©ricas de uniĆ³n al factor H (fHBP) que contienen un dominio B heterĆ³logo, y mĆ©todos de uso
NZ591103A (en) 2008-07-21 2013-02-22 Brigham & Womens Hospital Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiŔčenja za ogljikohidrat iz Streptococcus skupine A
NZ604186A (en) 2008-12-09 2014-07-25 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
CN102300585A (zh) 2008-12-17 2011-12-28 čÆŗåŽęœ‰é™å…¬åø åŒ…å«č”€ēŗ¢č›‹ē™½å—体ēš„č„‘č†œē‚ŽēƒčŒē–«č‹—
CN102307477B (zh) 2009-01-05 2015-07-29 埃ēš®ę‰˜å‰å°¼č„æę–Æč‚”ä»½ęœ‰é™å…¬åø 佐剂ē»„合ē‰©åŠä½æē”Øę–¹ę³•
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinaƧƵes de proteĆ­na de ligaĆ§Ć£o de fator h meningocĆ³cico e conjugados de sacarĆ­deos pneumocĆ³cicos
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
ES2642076T3 (es) 2009-06-22 2017-11-15 Wyeth Llc Composiciones inmunogƩnicas de antƭgenos de Staphylococcus aureus
TW201544119A (zh) 2009-06-22 2015-12-01 Wyeth Llc ēµ„合ē‰©åŠč£½å‚™é‡‘é»ƒč‰²č‘”萄ēƒčŒč”€ęø…åž‹ļ¼•åŠļ¼˜čŽ¢č†œå¤šé†£ēµåˆē‰©ä¹‹å…ē–«åŽŸę€§ēµ„合ē‰©ä¹‹ę–¹ę³•
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
AU2010277254B2 (en) 2009-07-30 2015-05-07 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
NZ620441A (en) 2009-09-03 2015-08-28 Pfizer Vaccines Llc Pcsk9 vaccine
JP2013504556A (ja) 2009-09-10 2013-02-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ 갗道ē–¾ę‚£ć«åÆ¾ć™ć‚‹ēµ„ćæåˆć‚ć›ćƒÆć‚Æćƒćƒ³
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
US9060965B2 (en) 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
EP3257525A3 (en) 2009-12-22 2018-02-28 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR112012024348B1 (pt) 2010-03-30 2022-11-08 Children's Hospital & Research Center At Oakland ComposiĆ§Ć£o imunogĆŖnica, seu uso, proteĆ­na de ligaĆ§Ć£o ao fator h de ocorrĆŖncia nĆ£o natural, e cĆ©lula bacteriana geneticamente modificada
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP6027961B2 (ja) 2010-04-07 2016-11-16 ć‚·ć‚§ćƒ³, 惦ć‚ØSHEN, Yue ē²˜č†œćø化合ē‰©ć‚’é€ć‚‹ćŸć‚ć®åŖ’ä½“ć€ćć‚Œć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•ć€åŠć³ć‚·ć‚¹ćƒ†ćƒ 
JP2013530949A (ja) * 2010-05-20 2013-08-01 ć‚Ø惫 ćƒ©ć‚¦ćƒ³ćƒ‰ ć‚øćƒ„ćƒ¼ćƒ³ ęŠ—åŽŸē‰¹ē•°ēš„ļ¼“ļ½’ļ½…ļ½‡äø¦ć³ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•åŠć³ć‚·ć‚¹ćƒ†ćƒ 
DK3170508T3 (da) * 2010-06-04 2020-01-02 Wyeth Llc Vaccineformuleringer
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa DĆ¼ÅŸĆ¼k antijen ve/ veya adjuvan dozları olan karma aşılar.
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
KR101711250B1 (ko) 2011-05-06 2017-03-02 ķŽ˜ķŠøė„“ ģ  ė‚˜ė””ģ—ė¹„ģ¹˜ ģ•„ķŒŒė¦° ģ‹œź²”ė¼ ģ†Œė„¤ģ“ ė°•ķ…Œė¦¬ģ•„ģ˜ ģ„øķ¬ģ™ø ė‹¤ė‹¹ė„˜, ģ“ė„¼ ģ œģ”°ķ•˜ėŠ” ė°©ė²•, ģ“ė„¼ ķ•Øģœ ķ•œ ė°±ģ‹  ė° ģ•½ģ œ ģ”°ģ„±ė¬¼
WO2012178118A1 (en) 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
CN103917245B (zh) 2011-09-14 2017-06-06 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡ē³–ā€‘蛋ē™½č“Øē³–ē¼€åˆē‰©ēš„ę–¹ę³•
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
CA2858519A1 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
ES2837825T3 (es) 2012-04-26 2021-07-01 Glaxosmithkline Biologicals Sa AntĆ­genos y combinaciones de antĆ­genos
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
HUE044612T2 (hu) 2012-05-04 2019-11-28 Pfizer Prosztata-asszociĆ”lt antigĆ©nek Ć©s vakcina-alapĆŗ immunterĆ”piĆ”s rendek
BR112014029313A2 (pt) 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinaĆ§Ć£o com sorogrupo b meningococcus e d/t/p
BR112015004593A2 (pt) 2012-10-03 2018-05-22 Novartis Ag composiƧƵes imunogĆŖnicas
KR20150065878A (ko) 2012-10-12 2015-06-15 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ģ”°ķ•© ė°±ģ‹ ģ—ģ„œ ģ‚¬ģš©ķ•˜źø° ģœ„ķ•œ ź°€źµė˜ģ§€ ģ•Šģ€ ė¬“ģ„øķ¬ ė°±ģ¼ķ•“ ķ•­ģ›
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
MX365842B (es) * 2012-10-17 2019-06-17 Glaxosmithkline Biologicals Sa Composicion inmunogenica que comprende 1 o mas conjugados de sacaridos capsulares de streptococcus pneumoniae y un componente proteico que comprende proteinas e y/o pila de haemophilus influenzae.
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Ƈan benzeri reseptƶr agonistleri iƧeren immĆ¼nolojik kompozisyonların intradermal yoldan verilmesi.
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
EP3689375A1 (en) 2013-05-15 2020-08-05 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
HUE051728T2 (hu) 2014-01-21 2021-03-29 Pfizer KonjugĆ”lt burokszaccharid antigĆ©neket tartalmazĆ³ immunogĆ©n kĆ©szĆ­tmĆ©nyek Ć©s alkalmazĆ”saik
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA2937184A1 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
JP6786394B2 (ja) 2014-02-28 2020-11-18 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ę”¹å¤‰é«„č†œē‚ŽčŒļ½†ļ¼Øļ½‚ļ½ćƒćƒŖ惚惗惁惉
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
WO2016014719A1 (en) 2014-07-23 2016-01-28 Children's Hospital & Research Center Oakland Factor h binding protein variants and methods of use thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
MX395525B (es) 2015-01-15 2025-03-25 Pfizer Composiciones inmunogenicas para usar en vacunas neumococicas.
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
JP2018522885A (ja) 2015-07-07 2018-08-16 ć‚¢ćƒ•ć‚£ćƒŖć‚¹ćƒ»ć‚¢ć‚Æćƒć‚§ćƒ³ć‚²ć‚¼ćƒ«ć‚·ćƒ£ćƒ•ćƒˆļ¼”ļ½†ļ½†ļ½‰ļ½’ļ½‰ļ½“ ļ¼”ļ½‡ ļ¼©ļ½‡ļ¼„介åœØꀧē–¾ę‚£ć®å‡¦ē½®ćŠć‚ˆć³äŗˆé˜²ć®ćŸć‚ć®ćƒÆć‚Æćƒćƒ³
IL303998A (en) 2015-07-21 2023-08-01 Pfizer Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
HK1248531A1 (zh) 2015-08-25 2018-10-19 å·“ęƔ唔ā€§é˜æę ¼ę‹‰ę²ƒå°” 免ē–«č°ƒčŠ‚ē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
CN108290960B (zh) 2015-10-08 2023-06-09 č‰¾ä¼Æ唔大学ē†äŗ‹ä¼š äø™åž‹č‚ē‚Žē—…ęƒe1/e2异äŗŒčšä½“及其ē”Ÿäŗ§ę–¹ę³•
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
DK3405212T3 (da) 2016-01-19 2020-08-24 Pfizer Cancervacciner
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
PH12019500238B1 (en) 2016-08-05 2023-05-10 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
JP7116278B2 (ja) 2016-10-07 2022-08-10 ć‚Øćƒ³ćƒ†ćƒ­ćƒ¼ćƒ  ć‚Øć‚¹ć‚Øćƒ¼ ē™Œę²»ē™‚ć®ćŸć‚ć®å…ē–«åŽŸę€§åŒ–合ē‰©
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
HUE059252T2 (hu) 2017-01-20 2022-11-28 Pfizer ImmunogƩn kƩszƭtmƩnyek pneumokokkusz vakcinƔkban tƶrtƩnƵ alkalmazƔsra
JP7010961B2 (ja) 2017-01-31 2022-02-10 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ é«„č†œē‚ŽčŒēµ„ęˆē‰©ćŠć‚ˆć³ćć®ę–¹ę³•
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 ę Ŗ式会ē¤¾Lg化学 多价č‚ŗē‚Žé“¾ēƒčŒē–«č‹—ē»„合ē‰©
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) 2017-06-10 2024-07-19 åˆ›čµå…¬åø ęä¾›ę”¹å–„ēš„免ē–«åŽŸę€§å’Œäŗ²åˆåŠ›ēš„å…·ęœ‰äŗŒä»·ęˆ–多价ē¼€åˆē‰©å¤šē³–ēš„多价ē¼€åˆē‰©ē–«č‹—
MX2020001820A (es) 2017-08-14 2020-03-20 Glaxosmithkline Biologicals Sa Metodos para reforzar las respuestas inmunitarias.
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2019139692A2 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
JP7288451B2 (ja) 2018-02-05 2023-06-07 ć‚µćƒŽćƒ•ć‚£ ćƒ‘ć‚¹ćƒ„ćƒ¼ćƒ« ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒƒćƒ‰ 多侔č‚ŗē‚ŽēƒčŒå¤šē³–体ļ¼ć‚æćƒ³ćƒ‘ć‚Æč³Ŗč¤‡åˆä½“ēµ„ęˆē‰©
KR102486891B1 (ko) 2018-02-05 2023-01-10 ģ‚¬ė…øķ”¼ ķŒŒģŠ¤ķ‡“ė„“ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¤ź°€ ķė “źµ¬ź· ģ„± ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
SMT202300021T1 (it) 2018-04-11 2023-03-17 Enterome S A Peptidi antigenici per la prevenzione e il trattamento del cancro
WO2019197563A2 (en) 2018-04-11 2019-10-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
TW202011985A (zh) 2018-04-18 2020-04-01 韓商ļ¼³ļ½‹ē”Ÿē‰©ē§‘å­øč‚”ä»½ęœ‰é™å…¬åø č‚ŗē‚ŽéˆēƒčŒēš„čŽ¢č†œå¤šé†£é”žä»„及其免ē–«åŽŸę€§ęŽ„合體
US12018134B2 (en) 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN113227125A (zh) 2018-12-12 2021-08-06 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽo-čæžęŽ„ēš„ē³–åŸŗ化ēš„äæ®é„°ēš„č½½ä½“č›‹ē™½
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220296695A1 (en) 2018-12-19 2022-09-22 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020146814A1 (en) 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
JP2022528158A (ja) 2019-04-10 2022-06-08 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆåŒ–čŽ¢č†œē³–ęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ć€ćć‚Œć‚’å«ć‚€ć‚­ćƒƒćƒˆćŠć‚ˆć³ćć®ä½æē”Ø
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
JP2022532142A (ja) 2019-05-10 2022-07-13 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć®č£½é€ 
JP2022543264A (ja) 2019-08-05 2022-10-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ćƒ—ćƒ­ćƒ†ć‚¤ćƒ³ļ½„ćƒćƒŖćƒšćƒ—ćƒćƒ‰ć‚’å«ć‚€ēµ„ęˆē‰©ć‚’čŖæč£½ć™ć‚‹ćƒ—ćƒ­ć‚»ć‚¹
WO2021023691A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Immunogenic composition
CN115605222A (zh) 2019-09-27 2023-01-13 č¾‰ē‘žå…¬åøļ¼ˆUsļ¼‰ 脑膜ē‚Žå„ˆē‘Ÿę°čŒē»„合ē‰©åŠå…¶ę–¹ę³•
US20230105457A1 (en) 2019-10-16 2023-04-06 Enterome S.A. Immunogenic Compounds For Treatment Of Adrenal Cancer
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
PL4021487T3 (pl) 2019-11-15 2024-04-15 Enterome S.A. Peptydy antygenowe do zapobiegania i leczenia nowotworĆ³w złośliwych wywodzących się z limfocytĆ³w b
JP2023503086A (ja) 2019-11-22 2023-01-26 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ē“°čŒć‚µćƒƒć‚«ćƒŖćƒ‰č¤‡åˆē³–č³ŖćƒÆć‚Æćƒćƒ³ć®ē”Øę³•åŠć³ē”Ø量
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
EP4107192A1 (en) 2020-02-21 2022-12-28 Pfizer Inc. Purification of saccharides
JP2023514697A (ja) 2020-02-23 2023-04-07 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ 大č…ø菌ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ę–¹ę³•
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
EP4165064A2 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Dock tag system
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7664386B2 (ja) 2020-10-27 2025-04-17 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ 大č…ø菌ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ę–¹ę³•
WO2022097010A1 (en) 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
JP7804673B2 (ja) 2020-11-10 2026-01-22 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć•ć›ćŸčŽ¢č†œē³–ęŠ—åŽŸć‚’å«ć‚€å…ē–«åŽŸę€§ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ä½æē”Ø
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
JP2024510717A (ja) 2021-02-22 2024-03-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©ć€ä½æē”ØåŠć³ę–¹ę³•
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20240090A1 (es) 2021-05-28 2024-01-16 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
KR20240128715A (ko) 2022-01-13 2024-08-26 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ķ”¼ė§‰ ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģš©ė„
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
CA3246416A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic Peptides for Cancer Prevention and Treatment
IL316477A (en) 2022-05-11 2024-12-01 Pfizer Process for producing vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
KR20250107930A (ko) 2022-11-22 2025-07-14 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ ‘ķ•©ėœ ķ”¼ė§‰ ģ‚¬ģ¹“ė¼ģ“ė“œ ķ•­ģ›ģ„ ķ¬ķ•Øķ•˜ėŠ” ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ģš©ė„
KR20250113501A (ko) 2022-12-01 2025-07-25 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ķė “źµ¬ź·  ģ ‘ķ•©ģ²“ ė°±ģ‹  ģ œķ˜•
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20252779A1 (es) 2023-04-14 2025-12-22 Pfizer Inc Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025109417A1 (en) 2023-11-21 2025-05-30 Panacea Biotec Limited Immunogenic composition of haemophilus influenzae conjugated to protein d
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
CN120404993B (zh) * 2025-07-03 2025-10-03 ęˆéƒ½čæˆē§‘åŗ·ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹ę ·ęœ¬äø­mplēš„ę–¹ę³•åŠå…¶ē›ø关åŗ”ē”Ø

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2160570T3 (es) * 1988-12-16 2001-11-16 Nederlanden Staat Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
CZ282235B6 (cs) 1992-06-25 1997-06-11 Smithkline Beecham Biologicals (S.A.) OčkovacĆ­ prostředek, jeho použitĆ­ k vĆ½robě vakcĆ­ny, zpÅÆsob lĆ©Äby patogennĆ­ch infekcĆ­ tĆ­mto prostředkem a zpÅÆsob jeho vĆ½roby
DK0618813T3 (da) * 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bƦrer for gruppe A streptococcal vaccine
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzĆ¼ndung
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von lƶslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
WO1996040242A1 (en) 1995-06-07 1996-12-19 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
WO1996040928A1 (en) 1995-06-07 1996-12-19 Biochem Vaccines Inc. Streptococcal heat shock proteins members of the hsp70 family
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
EP0912608B1 (en) 1996-05-01 2006-04-19 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
BR9809914A (pt) 1997-06-03 2001-09-18 Connaught Lab Genes de moracella receptores de lactoferrina
JP2001510031A (ja) 1997-07-21 2001-07-31 ćƒŽćƒ¼ć‚¹ćƒ»ć‚¢ćƒ”ćƒŖć‚«ćƒ³ćƒ»ćƒ“ć‚”ć‚Æć‚·ćƒ³ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ ćƒÆć‚Æćƒćƒ³ćØ恗恦恮äæ®é£¾ć•ć‚ŒćŸå…ē–«åŽŸćƒ‹ćƒ„ćƒ¼ćƒ¢ćƒŖć‚·ćƒ³ēµ„ęˆē‰©
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
ATE461709T1 (de) 1998-04-07 2010-04-15 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US6582706B1 (en) * 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
ES2339737T3 (es) * 1999-03-19 2010-05-25 Glaxosmithkline Biologicals Sa Vacuna contra polisacaridos capsulares de streptococcus pneumoniae.
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
PL203917B1 (pl) 2009-11-30
TWI286938B (en) 2007-09-21
HK1043731A1 (en) 2002-09-27
AR022963A1 (es) 2002-09-04
FR10C0008I1 (fr) 2010-03-26
BR0009154A (pt) 2001-12-26
CY1107390T1 (el) 2010-07-28
DK1162999T3 (da) 2007-03-26
EP1880735A3 (en) 2008-03-12
ES2339737T3 (es) 2010-05-25
SI1162999T1 (sl) 2007-04-30
US20060093626A1 (en) 2006-05-04
NO20014322L (no) 2001-11-14
NO330736B1 (no) 2011-06-27
EP1880735A2 (en) 2008-01-23
EP2277535A3 (en) 2011-03-09
AU3291900A (en) 2000-10-09
BR0009163A (pt) 2001-12-26
EP1162999B1 (en) 2006-11-29
TR200102736T2 (tr) 2002-04-22
WO2000056358A2 (en) 2000-09-28
AR022965A1 (es) 2002-09-04
EP1776962A1 (en) 2007-04-25
CZ20013378A3 (cs) 2002-03-13
US20100119544A1 (en) 2010-05-13
US20030147922A1 (en) 2003-08-07
WO2000056359A3 (en) 2001-02-01
CY2009014I2 (el) 2010-07-28
KR20020000549A (ko) 2002-01-05
NO2011014I1 (no) 2011-09-19
SI1163000T1 (sl) 2008-06-30
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
NL300415I1 (nl) 2009-12-01
HUS1500040I1 (hu) 2018-05-28
CN1192798C (zh) 2005-03-16
JP2011057713A (ja) 2011-03-24
NO2011014I2 (no) 2011-08-30
MY125202A (en) 2006-07-31
CZ20013379A3 (cs) 2002-03-13
EP2277535A2 (en) 2011-01-26
ATE346608T1 (de) 2006-12-15
DE122009000054I1 (de) 2009-12-31
HK1043728B (en) 2007-06-22
US20050031646A1 (en) 2005-02-10
EP1163000A2 (en) 2001-12-19
DE60038166T2 (de) 2009-03-12
EP1162998A2 (en) 2001-12-19
FR10C0008I2 (fr) 2012-10-26
NO20014325L (no) 2001-11-14
NO330532B1 (no) 2011-05-09
CN1191852C (zh) 2005-03-09
CN1351503A (zh) 2002-05-29
TR200102739T2 (tr) 2001-12-21
CN1351501A (zh) 2002-05-29
HK1043728A1 (en) 2002-09-27
IL145044A (en) 2007-03-08
BE1025464I2 (enExample) 2019-03-06
PL355178A1 (en) 2004-04-05
PT1162999E (pt) 2007-02-28
JP4846906B2 (ja) 2011-12-28
BRPI0009163B1 (pt) 2019-04-09
ES2300255T3 (es) 2008-06-16
IL145044A0 (en) 2002-06-30
ATE387214T1 (de) 2008-03-15
IL145043A0 (en) 2002-06-30
JP2002540074A (ja) 2002-11-26
PL355264A1 (en) 2004-04-05
HUP0200664A2 (en) 2002-06-29
WO2000056360A2 (en) 2000-09-28
CZ301445B6 (cs) 2010-03-03
BR0009166A (pt) 2001-12-26
AR022964A1 (es) 2002-09-04
AU3430700A (en) 2000-10-09
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
HUP0200373A2 (en) 2002-06-29
KR100798212B1 (ko) 2008-01-24
JP5551579B2 (ja) 2014-07-16
JP2002539273A (ja) 2002-11-19
NZ513841A (en) 2001-09-28
IL145043A (en) 2007-06-17
KR20020000785A (ko) 2002-01-05
CN1391481A (zh) 2003-01-15
EP1163000B1 (en) 2008-02-27
DE60032120T2 (de) 2007-09-20
PL204890B1 (pl) 2010-02-26
US20060002961A1 (en) 2006-01-05
WO2000056359A2 (en) 2000-09-28
CA2366314C (en) 2012-01-10
TR200102735T2 (tr) 2002-04-22
BRPI0009163B8 (pt) 2021-05-25
NO20014322D0 (no) 2001-09-05
CA2365296A1 (en) 2000-09-28
AU750762B2 (en) 2002-07-25
EP1162998B1 (en) 2010-03-03
HU228499B1 (en) 2013-03-28
NO20014323D0 (no) 2001-09-05
CA2366314A1 (en) 2000-09-28
AU750788B2 (en) 2002-07-25
CY2009014I1 (el) 2010-07-28
IL145045A0 (en) 2002-06-30
TWI281403B (en) 2007-05-21
US20110217329A1 (en) 2011-09-08
TWI235064B (en) 2005-07-01
KR20020001785A (ko) 2002-01-09
DE60032120D1 (de) 2007-01-11
LU91652I9 (enExample) 2019-01-03
NO20014325D0 (no) 2001-09-05
US9168313B2 (en) 2015-10-27
NZ513842A (en) 2004-05-28
CZ20013380A3 (cs) 2002-03-13
MXPA01009452A (es) 2002-08-06
AU750913B2 (en) 2002-08-01
HK1043730A1 (zh) 2002-09-27
LU91652I2 (fr) 2010-10-13
DE60038166D1 (de) 2008-04-10
PL355180A1 (en) 2004-04-05
MY125387A (en) 2006-07-31
DK1163000T3 (da) 2008-04-28
JP2002540075A (ja) 2002-11-26
ATE459373T1 (de) 2010-03-15
AU3813600A (en) 2000-10-09
DE60043930D1 (de) 2010-04-15
HU229968B1 (hu) 2015-03-30
NZ513840A (en) 2004-02-27
ES2275499T3 (es) 2007-06-16
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
CY1107561T1 (el) 2013-03-13
US8926985B2 (en) 2015-01-06
EP1162999A2 (en) 2001-12-19
HK1043731B (en) 2009-01-23
WO2000056360A3 (en) 2001-01-25
WO2000056358A3 (en) 2001-01-04
KR100642044B1 (ko) 2006-11-10
CZ303653B6 (cs) 2013-01-30
HUP0200367A2 (en) 2002-05-29

Similar Documents

Publication Publication Date Title
BE2018C020I2 (enExample)
BE2015C057I2 (enExample)
BE2016C007I2 (enExample)
BE2015C018I2 (enExample)
BE2014C017I2 (enExample)
BE2013C051I2 (enExample)
BE2013C020I2 (enExample)
BE2013C015I2 (enExample)
BE2013C001I2 (enExample)
BE2012C036I2 (enExample)
BE2008C046I2 (enExample)
BE1025464I2 (enExample)
BE2010C011I2 (enExample)
BRPI0017527B8 (enExample)
BE2008C047I2 (enExample)
BE2011C004I2 (enExample)
BRPI0001672A2 (enExample)
JP2002513244A5 (enExample)
JP2002506962A5 (enExample)
BRPI0001542A2 (enExample)
BRPI0012675B8 (enExample)
BRPI0017522A2 (enExample)
BRPI0303609A (enExample)
BRMU7902607U2 (enExample)
BRPI9917761A2 (enExample)